All In Biotech

Drug Trial Radar · NCT07623616

A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

A Phase 2, Multicenter, Open-Label Study of Ziftomenib Monotherapy in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia With NPM1 Mutation

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

Apr 23, 2026

Primary completion

Mar 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Kyowa Kirin Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is the first study to administer ziftomenib to Japanese patients. In this study, the efficacy, safety, and pharmacokinetics of ziftomenib will be evaluated in patients with relapsed or refractory NPM1-mutated acute myeloid leukemia

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

  • ziftomenibDrug

    Oral adminitration once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CR+CRh rateTime frame: Best overall response assessed every 28 days from first dose until disease progression or withdrawall, an average of 16weeks

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Chiba Aoba Municipal Hospital

    Chiba, Japan

  • Gifu Municipal Hospital

    Gifu, Japan

  • Hyogo Medical University Hospital

    Hyōgo, Japan

  • Mito Medical Center

    Ibaraki, Japan

  • Imamura General Hospital

    Kagoshima, Japan

  • Kanagawa Cancer Center

    Kanagawa, Japan

  • Kyoto University Hospital

    Kyoto, Japan

  • Tohoku University Hospital

    Miyagi, Japan

  • Matsumoto National Hospital

    Nagano, Japan

  • Nagasaki University Hospital

    Nagasaki, Japan

  • Kurashiki Central Hospital

    Okayama, Japan

  • Okayama University Hospital

    Okayama, Japan

  • Kansai Medical University Hospital

    Osaka, Japan

  • Osaka Metropolitan University Hospital

    Osaka, Japan

  • Jichi Medical University Saitama Medical Center

    Saitama, Japan

  • Dokkyo Medical University Hospital

    Tochigi, Japan

  • Jichi Medical University Hospital

    Tochigi, Japan

  • Keio University Hospital

    Tokyo, Japan

  • Nippon Medical School Hospital

    Tokyo, Japan

  • Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.